Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortization of Deferred Charges (2024 - 2025)

Historic Amortization of Deferred Charges for Arrowhead Pharmaceuticals (ARWR) over the last 2 years, with Q4 2025 value amounting to $14.9 million.

  • Arrowhead Pharmaceuticals' Amortization of Deferred Charges fell 816.96% to $14.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.0 million, marking a year-over-year increase of 14267.65%. This contributed to the annual value of $63.3 million for FY2025, which is 57967.16% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Amortization of Deferred Charges of $14.9 million as of Q4 2025, which was down 816.96% from $14.6 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Amortization of Deferred Charges registered a high of $16.4 million during Q2 2025, and its lowest value of $9.3 million during Q3 2024.